Excessive use of reliever inhalers for asthma is linked to a significantly increased risk of dying from the disease, a new study revealed today. Researchers found that over-use of short acting ...

For millions of asthma sufferers worldwide, the distinctive puff of an inhaler represents a lifeline, providing instant relief from constricted airways. Dr Juma Bwika, a pulmonologist at Aga Khan ...

A trial of AstraZeneca and Avillion's first-in-class asthma rescue inhaler Airsupra has been halted early after the drug outperformed a standard therapy. Investigator sites are essential for ...

Topline results were announced from a phase 3b trial evaluating albuterol/budesonide metered dose inhaler in ... (ICS) asthma rescue therapy approved under the brand name Airsupra ...

A trial of AstraZeneca and Avillion's first-in-class asthma rescue inhaler Airsupra has been halted early after the drug outperformed a standard therapy. The phase 3b BATURA study showed Airsupra ...

Take the market for albuterol inhalers, filled with fast-acting drugs meant to stop an asthma attack in its tracks. Before the propellant switch, annual sales for the three brand-name inhalers had ...

Details of the study were presented in a session at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting (ACAAI 2024) in Boston. Reliever inhalers, including ...

Those using a rescue inhaler during an asthma attack, especially, may want a propellant to help push the medicine into their airways. This is why GSK Plc is focusing on lowering the emissions of ...

Early fall is when asthma flare-ups peak in the US ... Pharmaceutical companies are looking to change that with lower-emitting inhalers that they plan to roll out by the end of the decade.